Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alembic Pharmaceuticals Ltd.

NSE: APLLTD | BSE: 533573 | ISIN: INE901L01018 | Industry: Pharmaceuticals
| Mid-range Performer

943.9000 -6.10 (-0.64%)

NSE Sep 23, 2025 10:58 AM

27.61% Fall from 52W High

Volume: 6,919

Alembic Pharmaceuticals Ltd.

07 Nov 2024

943.90

-0.64%

Alembic Pharma (BUY): The worst is over; H2FY25 to be better than H1FY25

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2FY25 results were below our estimates on all fronts; however, ALPM expects H2 to be better than H1FY25 driven by healthy product mix

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.